Advanced bio-simulation methods are expected to substantially improve radiotherapy treatment planning. To this end a novel spatio-temporal patientspecific simulation model of the in vivo response of malignant tumours to radiotherapy schemes has been recently developed by our group. This paper discusses recent improvements to the model: an optimized algorithm leading to conformal shrinkage of the tumour as a response to radiotherapy, the introduction of the oxygen enhancement ratio (OER), a realistic initial cell phase distribution and finally an advanced imaging-based algorithm simulating the neovascularization field. A parametric study of the influence of the cell cycle duration T c , OER, OER β for the beta LQ parameter on tumour growth, shrinkage and response to irradiation under two different fractionation schemes has been made. The model has been applied to two glioblastoma multiforme (GBM) cases, one with wild type (wt) and another one with mutated (mt) p53 gene. Furthermore, the model has been applied to a hypothetical GBM tumour with α and β values corresponding to those of generic radiosensitive tumours. According to the model predictions, a whole tumour with shorter T c tends to repopulate faster, as is to be expected. Furthermore, a higher OER value for the dormant cells leads to a more radioresistant whole tumour. A small variation of the OER β value does not seem to play a major role in the tumour response. Accelerated fractionation proved to be superior to the standard scheme for the whole range of the OER values considered. Finally, the tumour with mt p53 was shown to be more radioresistant compared to the tumour with wt p53. Although all simulation predictions agree at least
qualitatively with the clinical experience and literature, a long-term clinical adaptation and quantitative validation procedure is in progress.
Introduction
Optimization of the physical dose distribution constitutes the basis of most current treatment planning. Where biological factors are considered, they tend to rely on rather crude models of tumour and normal tissue response; such algorithms practically ignore the highly complicated dynamic behaviour of malignant cells and tissues. The introduction of advanced bio-simulation models based on cell proliferation mechanisms and on information drawn from the cellular and molecular properties of individual malignancies and individual patients is expected to improve the results of radiation therapy.
In recent decades intensive efforts have been made to model tumour growth and tumour and normal tissue response to therapeutic modalities such as radiotherapy. In spite of this, accurate models of dynamic processes are still lacking, due to the complexity of the problem and the paucity of large series of clinical data.
The discrete state simulation model introduced by Duechting (1990) and Duechting et al (1995) is based on a consideration of the distinct phases of the cell cycle, but this tumour behaviour model concerns only the in vitro case or the early avascular stages of small in vivo tumours. Kocher and Treuer (1995) and Kocher et al (2000) presented a simulation model of the development of a tumour spheroid and its response to radiosurgery. However, the detailed geometry of the clinical tumour as depicted by imaging data is not taken into account in this model; an equivalent spherical tumour being considered instead of the generally arbitrarily shaped actual tumour. Furthermore, the detailed cell cycle phase biology has not been taken into account (discrete phases G1, M, G2, M). Grouping of the cells into only proliferating and dormant classes is considered instead. Additionally, none of the above-mentioned models has been applied to large clinical tumours of varied geometrical shapes and none of them simulates conformal shrinkage for an arbitrarily shaped clinical tumour undergoing treatment. In the tumour growth models presented by Kansal et al (2000a Kansal et al ( , 2000b , a discretizing grid is used in which each geometrical cell is able to contain a large number of biological cells, but the grid has not been used to discretize clinical tumours of arbitrary shape. The response of the tumour to irradiation has not been addressed in this model. An effort to overcome these shortcomings has previously been made by our group through the development of a four-dimensional patient-specific in vivo simulation model (Stamatakos et al 2001a (Stamatakos et al , 2001b (Stamatakos et al , 2002 . All parameters used in the model have already been defined and can be determined by experimentalists and/or clinicians. Therefore, use of new mathematically dictated parameters of eventually ambiguous physical meaning is avoided. Furthermore, the authors believe that the development of an experimental and clinical biology based model provides substantial insight into the interdependence of the mechanisms involved, even if some parameters cannot currently be accurately quantified for individual patients.
The latest improvements, presented in this paper, include an optimized algorithm simulating the conformal shrinkage of a tumour in response to radiotherapy, the introduction of the oxygen enhancement ratio (OER), a realistic initial cell phase distribution and finally an advanced imaging-based algorithm simulating the neo-vascularization field.
A parametric study of the influence of the cell cycle duration (T c ), OER, OER β (for the beta LQ parameter on the tumour growth) and shrinkage in response to irradiation under accelerated and standard fractionation schemes is also made. The model has been applied to two glioblastoma multiforme (GBM) cases, one with wild type (wt) and another one with mutated (mt) p53 gene. Furthermore, the model has been applied to a hypothetical GBM tumour with α and β values corresponding to those of generic radiosensitive tumours. It is pointed out that different tumour types cannot be easily considered at present for the following reasons. First, although the basics of the model are applicable to a large spectrum of human tumours, the software developed up to now has also taken into account elements of the anatomy and the mechanical behaviour of the human brain. Therefore, tumours arising in other anatomical regions of the human body would require the development of substantial new software. Regarding brain, the assumption of very poor differentiation made in the current version of the model does not apply equally well to tumours other than glioblastoma multiforme. Furthermore, the specific pathophysiology of glioblastoma multiforme is highly complicated, and the proposed model is the product of many years' work of our group. The model predictions are compared with both clinical experience and the literature, and the simulation model is, at least qualitatively, validated. Nevertheless, as pertinent series of clinical data are rather sparse, a long-term clinical adaptation and quantitative validation procedure are in progress.
The basics of the model
The basic model assumptions have already been discussed in previous work (Stamatakos et al 2002, http ://www.in-silico-oncology.iccs.ntua.gr/). In the following only a general outline of selected assumptions is given.
Data acquisition
The imaging data (e.g., CT, MRI, PET slices, possibly fused), including the definition of the tumour contour and the anatomical structures of interest, the histopathologic (e.g., type of tumour) and the genetic data (e.g., p53 status) of the patient are collected. The above information is introduced into the 3D visualization package (AVS-Express), which performs the visualization of both the tumour and the surrounding region of interest by combining volume and surface rendering techniques. The planned distribution of the absorbed dose (in Gy) in the region of interest is also acquired. Especially for the case of glioblastoma multiforme T1 MRI slices have been mainly used by our group up to now.
Tumour growth biology
According to the standard cytokinetic model, a cycling tumour cell passes through the phases G1 (gap 1), S (DNA synthesis), G2 (gap 2) and M (mitosis) (Watson et al 1987 , p 556, Lodish et al 1995 , p 178, Duechting et al 1995 , p 302, Perez and Brady 1998 , p 37-8, Steel 2002 .
There is always a chance that each tumour cell residing in any phase dies with some probability per hour due to ageing/spontaneous apoptosis. This probability represents the cell loss rate due to apoptosis and is the product of the cell loss factor due to apoptosis and the cell birth rate (Steel 2002) . The cell birth rate can be considered as the ratio of the growth fraction to the cell cycle duration (Steel 2002, p 12-13, 254) . Side effects, immunologic reactions, heterogeneity and the formation of metastases are neglected.
Based on the experimental observation that the diffusion limit of oxygen is about 100 µm from the capillaries and that there is usually progressive hypoxia from the outer tumour layer to the centre of the tumour (Helmlinger et al 1997 , Michelson and Leith 1997 , Hobbs et al 1998 , Baish and Jain 2000 , Hashizume et al 2000 , Carmeliet and Jain 2002 , an intermediate G0 layer (containing a substantial number of hypoxic cells) is considered. During the tumour growth process, new capillaries are assumed to emerge so that both the tumour volume (characterized by pronounced metabolic activity in the beginning of the simulated period) and the volume added to the tumour are considered to be able to sustain proliferation.
Temporal characteristics
(i) Time is quantized and measured in appropriate units. In all applications 1 h has been adopted as the unit of time. (ii) Biological cells constituting each phase class within the same geometrical cell are assumed to be synchronized. (iii) For each geometrical cell and for the pool of the radiation hit cells, the time remaining until the next cell division takes place is the result of weighting the time until cell division of each synchronized cell subgroup of the pool by the number of cells constituting it. (iv) For each geometrical cell under examination, the remaining time in the current phase is reduced by one time unit (T ) after each step.
Cell cycle phase equivalence classes
The tumour cell volume usually assumed by the medical physicists has been adopted. According to this assumption the volume of 1 mm 3 contains 10 6 tumour cells (Nahum and Sanchez-Nieto 2001). If we consider approximately cubic tumour cells, then the edge of each cell (including the corresponding intracellular space) would be 10 −2 mm (=10 µm). This value is also satisfactorily compatible with histopathology preparations of glioblastoma multiforme (Curran and Crocker 2000, p 87) .
The description of the biological activity of the tumour (Williams and Bjerknes 1972 , Watson et al 1987 , Lodish et al 1995 , Perez and Brady 1998 , Steel 2002 ) is implemented by introducing the notion of the 'geometrical cell' (Stamatakos et al 2002) . A three-dimensional discretizing mesh is superimposed on the anatomical region of interest. Each geometrical cell of the mesh belonging to the tumour contains a number of biological cells 'residing' in various phases within or without the cell cycle (G1, S, G2, mitosis, g0, necrosis, apoptosis, lysis). Within each geometrical cell, a number of classes of biological cells (compartments), each one characterized by the phase in which its cells are found (within or out of the cell cycle), are defined. Sufficient registers are used in order to characterize the state of each geometrical cell and each phase class within it (e.g., the number of biological cells in phase G1, the time spent in phase G1, etc). The number of biological cells constituting each phase class is initially estimated according to the position of the geometrical cell within the tumour and from the metabolic activity in the local area (e.g., based on PET, functional MRI etc).
Tumour expansion and shrinkage
A simplifying assumption dictates that each geometrical cell of the mesh can 'normally' accommodate a constant number of biological cells (NBC). In cases where the actual number of alive and dead (but still morphologically existing) tumour cells contained within a given geometrical cell is reduced to less than NBC/2, then a procedure is invoked which attempts to 'unload' the remaining biological cells into the neighbouring geometrical cells. This procedure might lead to removal of geometrical cells and differential tumour shrinkage (figures 1(a), (b) and (c)). This can happen, e.g., after irradiation of a radioresponsive tumour. On the other hand, if the number of alive and dead cells within a given geometrical cell exceeds NBC+NBC/2,
(c) (f ) Figure 1 . Visualization of the tumour shrinkage and expansion algorithm. The indicative geometrical cell evacuation and generation rules are: (i) a simplifying assumption dictates that each geometrical cell of the mesh can 'normally' accommodate a constant number of biological cells (NBC), (ii) a geometrical cell of the discretization mesh covering the tumour is evacuated if it contains less than (50/100) NBC tumour cells, (iii) a geometrical cell generates a new geometrical cell if its contents exceed (150/100) NBC, (iv) a geometrical cell unloads its excess or insufficient contents (biological cells) to its neighbouring cells according to the previous two rules, (v) a higher priority for the reception of the excess or insufficient contents of a geometrical cell is assigned to that of its neighbours that contains the least number of biological cells, (vi) the position of a newly generated geometrical cell relative to the position of its 'mother' is determined using a random number generator. The scheme explanation is as follows. Tumour shrinkage: (a) contents (biological cells) of the geometrical cell C2 = (25/100) NBC < (50/100) NBC. Apply rule (ii). then a new adjacent geometrical cell emerges (figures 1(d), (e) and (f )). In order to improve the model accuracy, deviations from NBC that are less than NBC/2 are currently being studied.
Recent advances

Imaging-based neovasculature distribution
Mammalian cells require oxygen and nutrients for their survival, and functional cells must therefore be located within a distance of 100 to 200 µm from the nearest capillary blood vessels, which is the diffusion limit for oxygen. For multicellular organisms to grow new blood vessels must be recruited by angiogenesis. Without blood vessels, tumours cannot grow beyond a critical size or metastasize to another organ (Carmeliet and Jain 2002) . In contrast to normal vessels, tumour vasculature is highly disorganized; vessels are tortuous and dilated, with uneven diameter, excessive branching and shunts. This is due to imbalance of angiogenic regulators. Consequently tumour blood flow is chaotic and variable (Baish and Jain 2000, Carmeliet and Jain 2002) and leads to hypoxic and acidic regions in tumours (Helmlinger et al 1997, Carmeliet and Jain 2002) .
Tumour vessel ultrastructure is also abnormal. The vessel walls have numerous 'openings' widened interendothelial junctions, and a discontinuous or absent basement membrane. These defects make tumour vessels 'leaky' (Hobbs et al 1998 , Hashizume et al 2000 , Carmeliet and Jain 2002 , and there is tremendous heterogeneity in leakiness over space and time (Hobbs et al 1998 , Hashizume et al 2000 , Carmeliet and Jain 2002 . Vascular permeability and angiogenesis depend on the type of tumour and on the host organ in which the tumour is growing (Hobbs et al 1998, Carmeliet and Jain 2002) .
Based on the previous observations, an intermediate layer, denoted by 'G0' is assumed to exist, which contains a substantial number of dormant cells around the necrotic area of the tumour as it appears on the imaging data (section 2.1). Definition of the imaging-based tumour layers dictates the number and the metabolic state of the individual biological cells included within each layer. During the simulation process, and in the case of tumour growth, the normal tissue capillaries are shifted away, and tumour capillaries are generated in their place (Michelson and Leith 1997, Carmeliet and Jain 2002) . Consequently, the new tumour cells are assumed to be sufficiently oxygenated and able to divide.
Radiobiology-explicit consideration of the oxygen effect
After irradiation, reproductively dead cells may continue functioning normally until their ultimate (biological) death. Biological death occurs most often after a few (usually one to three) mitotic divisions (Perez and Brady 1998, p 87) . Therefore, in this model reproductively dead cells according to the LQ model are assumed to undergo two further mitoses before their biological death (Stamatakos et al 2002) . Nevertheless, as biological and not reproductive cell death is detectable through imaging modalities such as MRI and PET, reproductively dead cells and their offspring that are still cycling are considered proliferating until their ultimate biological death. This is an interesting point emphasizing the conceptual differences that may arise between an engineering and a medical physics/clinical approach to the same biological phenomenon. The above convention should be borne in mind in the rest of the paper. Exploratory simulation runs have shown that if still cycling reproductively (but not yet biologically) dead cells are added to the unaffected proliferating cells; an increase in the number of the latter by up to a factor of 10 (1 log) is to be expected during a typical radiotherapy course.
The resistance of cells that are hypoxic at the time of therapy will influence the efficacy of treatment with radiation, chemotherapy and combined modality regimens. The response of cells to ionizing radiation in particular is strongly dependent on oxygen, any given dose killing substantially fewer hypoxic than oxic cells. The radiation dose that allows a particular level of survival tends to be reduced by the same factor at all levels of survival when oxygen is removed. This allows calculation of oxygen enhancement ratio (OER) for the same level of biological effect. For most cells OER for x-rays is around 3.0 (Kocher and Treuer 1995 , Kocher et al 2000 , Steel 2002 ). Palcic and Skarsgard (1984) , Revesz and Palcic (1985) and Steel (2002) report that OER reduces for radiation doses to 3.0 Gy or less. In practical terms, within a tumour microenvironment, the oxic cells are those which proliferate whereas the hypoxic cells are dormant, or G0, cells. It has been demonstrated experimentally that most solid tumours contain resistant hypoxic cells, with estimates of the hypoxic fractions ranging from below 1% to well over 50% of the total viable cell population. Additionally, evidence that hypoxia exists in human tumours to a degree that can influence radiation response comes from those clinical trials in which some form of hypoxia modification has been attempted and found to improve tumour response (Steel 2002) .
Attempts to measure hypoxia in human tumours have proved difficult. Recent methods rely on indirect methods: tumour vascularization, haemoglobin, oxygen saturation, tumour metabolic activity, degree of DNA damage, hypoxic markers or measures of pO 2 distribution (Steel 2002, p 162) . Knisely and Rockwell (2002) report that the resistance of gliomas to treatment with radiation and antineoplastic drugs may result in part from the effects of the extensive and severe hypoxia that is present in such tumours. They emphasize that the brain tumours contain extensive regions in which the tumour cells are subjected to an un-physiological degree of hypoxia, this being involved in the evolution of cells in low-grade malignancies to the resistant, aggressive phenotype characteristic of glioblastomas.
Extensive work has been done to measure hypoxia in human brain tumours (especially for gliomas) (Beppu et al 2002 , Potapov et al 1983 , Groshar et al 1993 , Yetkin and Mendelsohn 2002 , Valk et al 1992 , Leenders 1994 . Nygren and Ahnstrom (1997) suggest that OER can range from 2.0-3.0 and Palcic et al (1989) , Stuschke et al (1992) , and Speke and Hill (1995) reported a value for OER of 2.3, 2.7 and 2.75, respectively.
Subsequently, different α and β values for the oxic (G1, S, G2, M) and hypoxic (G0) cells are considered. The interrelation between the hypoxic and oxic LQ parameters is given by the following expressions (Kocher et al 2000) :
Some authors report different OER values for α and β (Chapman et al 1975 , Chapman 2003 . They mention that OER α ranges from 1.7 to 1.8, whereas OER β ranges from 3.0 to 3.5. Therefore, equations (1), (2) become:
Radiobiology-wild and mutated p53
The molecular basis of cell radiosensitivity has been extensively studied during the last decades (MacIlwrath et al 1994 , Brown and Wouters 1999 . The role of oncogenes and tumour suppressor genes in modulating the response of tumour cells to irradiation is of particular interest, since numerous tumours may be more successfully treated, if the status of the above genes is taken into consideration when deciding on the appropriate therapeutic strategy. Perhaps the best-known tumour-suppressor gene is p53. The roles of wild type (wt) p53 in modulating DNA repair, apoptosis and the G1 cell cycle arrest have each been implicated in the regulation of cellular response to ionizing radiation. An abnormal p53 has been related to a wide variety of tumours throughout the body. p53 mutations (mt) in human malignancies are frequently associated with poor prognosis, poor response to therapy and advanced stage of disease. There are numerous other genes possibly influencing cellular response to irradiation.
For the testing procedure of the developed model, a glioblastoma multiforme (GBM) case has been selected. The radiation response of GBMs has been extensively studied (Taghian et al 1995 , Smith et al 2001 .
A remarkable number of studies associate p53 mutations with increased radioresistance and poor clinical outcome for patients with GBM. Approximately 40-60% of GBMs have p53 mutations (Wu et al 1993) . Haas-Kogan et al (1999) investigated the influence of p53 status on radiation-induced apoptosis and G1 cell cycle arrest of GBM cells. They found that radiation-induced apoptosis of GBM cells occurred in a manner independent of wt p53, in contrast to G1 cell cycle arrest, which was p53 dependent. An increased radioresistance was observed in irradiated G1 cells lacking functional wt p53, manifested by a relatively lower α and α/β. Furthermore, Haas-Kogan et al (1999) studied the influence of p53 function on the effect of fractionated radiotherapy of GBM tumours and concluded that fractionated radiotherapy provides a selective advantage to GBM cells expressing mutant p53.
It is worthwhile to stress that the presented in vivo tumour growth and response to radiotherapy simulation model of our research group offers the advantage of readily adapting the parameters that take into account the influence of p53 status (LQ model parameters, possibility of apoptosis, G1 phase duration etc) and/or of other possible genetic determinants. Once the prognostic value of specific genetic data becomes well established, the status of the relevant genetic indicators can be easily incorporated into the tumour simulation model, leading to its substantial clinical refinement.
The parameters α and β of the LQ model have been derived from the corresponding literature for GBM tumours: 
Conformal tumour shrinkage: the centre of mass algorithm (CMA)
When tumour shrinkage takes place the shrinkage process in most cases tends to behave as a conformal contraction (Perez and Brady 1998, p 10) . In order to satisfactorily simulate this process in conjunction with the rest of the simulation strategy (figure 2) a so-called 'centre of mass algorithm' (CMA) is introduced. Its primary mission is to 'pull' individual tumour cells towards the centre of mass of the entire tumour. It is emphasized that the term 'centre of mass' is not used in a strictly rigorous context as it refers to a tumour of uniform mass density. The biological rationale for the cells to be 'pulled' towards the centre of mass of the tumour is that the surrounding normal tissues exert a rather uniform pressure upon the tumour in such a way that the brain tends to recover its (physiological) normal shape (homeostasis). Nevertheless, deviations of this rule due to local inhomogeneities are to be expected. It should be pointed out that the model does not consider the eventual appearance and behaviour of new tumour foci out of the space occupied by the primary tumour due to infiltration of adjacent tissues.
A geometrical cell is considered to belong to the main cohesive tumour mass if it is in two-dimensional side contact with at least one other geometrical cell of the main tumour mass. In figure 2 (shown in two dimensions for simplification reasons), the distance of the centre of the geometrical cell C 2 from the nearest geometrical cell occupied by the main tumour mass is larger than one geometrical cell. The content of each isolated geometrical cell tends to move towards the centre of the main cohesive tumour mass. Only shifts along the x+ or x−, y− or y+ or z− or z+ directions are allowed. Using the CMA the distance of the centre of C 2 from the centre of the main tumour along each of the six possible directions is calculated, the least distance then being selected. In cases where more than one distances have the same least value then the direction is selected randomly. After completion of the next discretization mesh scan, C 2 will be closer to the centre of mass of the tumour, and after a number of scans C 2 will be connected with the nearest cell of the main tumour mass.
Uniform cell distribution
During the initialization process, cells within the same cell cycle phase are not considered to be synchronized. A random number generator is used to produce a uniform cell distribution within the time units constituting each phase within or without the cell cycle (i.e. G0), this being a more realistic approach.
Simulation execution and visualization
Computational demands
The computer code has been developed in Microsoft Visual C++ 6.0. As far as the computational demands are concerned, execution of a typical six week radiation therapy course with a discretizing mesh of 96 × 96 × 96 geometrical cells each one of dimensions 1 mm × 1 mm × 1 mm on an AMD Athlon XP machine (2.5 GHz, 786 MB RAM) takes about 2 min.
Presentation of the model predictions-visualization
Once radiotherapy treatment has been prescribed, the dose distribution (in Gy) in the region of interest is provided. This distribution, in conjunction with the imaging, histopathologic and genetic data of the patient, is processed by the previously described software in order to 'predict' the most likely spatio-temporal response of the tumour. Software from Advanced Visual Systems TM has been used to provide a suite of sophisticated 3D solutions for facilitating the analysis and for presentation of the simulation results.
Numerical stability issues
The stability of the algorithm has been checked by scanning the discretizing mesh in different orders of coordinate scanning (e.g., x → y → z, z → y → x), and the variation of the predictions has been shown to be negligible. (It should be noted that due to the use of random number generators, exactly identical predictions are not to be expected after each simulation).
Results and qualitative validation: the case of in vivo glioblastoma multiforme
In order to provide a preliminary validation of the algorithms described so far, the following testing procedure has been devised and implemented. A case of glioblastoma multiforme (grade IV astrocytoma) recently irradiated, has been selected for which a specialist had delineated the imaging-based apparent boundary of the tumour. The necrotic area had also been identified, based on the corresponding MRI and PET data after irradiation (hysteron proteron in this specific case, only for validation purposes). As a first approximation, the neovasculature field has been assumed to coincide with the area of the tumour where pronounced metabolism had been apparent on the pertinent (e.g., PET) imaging data. A cube defining the anatomical region of interest has been superimposed on the imaging slices. The dimensions of each geometrical cell are 1 mm × 1 mm × 1 mm. Such a volume contains roughly 10 6 biological cells (Nahum and Sanchez-Nieto 2001) (NBC = 10 6 ). Both a standard (2 Gy once a day, 5 days per week, 60 Gy in total) and an accelerated fractionation (2 Gy twice a day-8 h interval, 5 days per week, 60 Gy in total) schemes have been simulated. The LQ model parameters of the tumour have been assumed to be α oxic = 0. and β hypoxic = (0.06/OER 2 ) Gy −2 for a generic radiosensitive tumour (Jones and Bleasdale 1997, Kocher et al 2000) have been considered. OER in all the previously mentioned cases can take the values 1.0, 2.5, 3.0 and 3.5.
Both the α oxic and β oxic parameters are assumed to remain constant throughout the cell cycle. Proliferating cells lethally hit by radiation have been assumed to undergo two further mitoses before entering the necrotic phase in agreement with Steel (2002) . For visualization purposes during the time interval between a lethal cell hit and necrosis or apoptosis, the cells are 'painted' as dead.
For the specific type of poorly differentiated tumour under consideration, and for simplification reasons, all non-clonogenic cells have been considered to be necrotic (sterile cells have not been taken into account). The contribution of the living non-clonogenic cells (cells that are able to undergo only a limited number of cell divisions) will be considered in a future version of the model. A typical mean clonogenic cell density (Nahum and Sanchez-Nieto 2001) is 10 7 cells/cm 3 (=10 4 cells/mm 3 ). We have assumed a clonogenic cell density of 2 × 10 4 cells/mm 3 in the 'proliferating cell layer'. This layer has lain between the external surface of the gross tumour volume and a hypothetical surface (HYP) enclosing its necrotic kernel and lying 1 mm further out. The tumour volume contained between HYP and the surface of the necrotic region has been assumed to contain large numbers of dormant G0 cells; therefore it is called 'G0 cell layer'. A clonogenic cell density of 10 4 cells/mm 3 in the G0 cell layer and 0.2 × 10 4 cells/mm 3 in the necrotic or dead cell layer of the tumour has also been assumed. Within each geometrical cell of the discretizing mesh, the initial distribution of the clonogenic cells through the various cell cycle phases depends on the layer of the tumour to which the geometrical cell belongs. The following rough assumptions concerning the distribution of cells within and without the cell cycle have been made. In the proliferating cell layer 70% of the clonogenic cells have been assumed to be in the cycling phases and 30% in the G0 phase. In the G0 cell layer 30% of the clonogenic cells have been assumed to be in the cycling phases and 70% in the G0 phase. Finally, in the necrotic cell layer 10% of the clonogenic cells have been assumed to be in the cycling phases and 90% in the G0 phase. The previous fractions reflect an initial effort to quantify histopathological observations concerning the cytokinetic distribution of the tumour cells in the various layers of a tumour. More realistic values are expected to arise during the clinical validation of the model.
Extensive work has been done to measure the cell cycle duration of tumour proliferating cells. Recent research efforts have been focused on the measurement of the cell cycle duration (T c ) especially for gliomas. Crafts et al (1977) , using the method of double radioautography, suggested that T c could range from 2-3 days. Hoshino (1992) performed double-labelling studies with BUdR and iododeoxyuridine and analysed the cell cycle progression in 29 gliomas. He revealed that the cell cycle duration calculated for gliomas with labelling indexes (LIs) of 1-20% was 1-2 days. Katzung (2001) suggested that proliferating tumour cells would spend their time in the various cell cycle phases as follows: time spent in G1: T G1 = 0.4T c , time spent in S: T S = 0.39T c , time spent in G2: T G2 = 0.19T c and time spent in M:
The
The cell loss factor (Steel 2002, p 13, 15, 253) has been taken as 0.3 as cell death products are removed from brain with substantial difficulty. This total cell loss factor has been expressed as the sum of the cell loss factor due to necrosis (0.2) and the cell loss factor due to apoptosis (0.1). It is noted that necrosis tends to be more pronounced than apoptosis for the specific type of tumour. The probabilities of cell loss per hour due to necrosis and due to apoptosis have been derived from the above-mentioned value of the cell loss factor according to Steel (2002) . More realistic values of the cell loss factor and the phase distribution of cells in the various tumour layers are expected to emerge after completion of the clinical adaptation process. The model has been executed for up to 60 simulated days, an interval which normally covers the treatment time and a few weeks after completion of the radiotherapy course. In the following the cell cycle duration has been assumed to be 48 h unless otherwise stated. The simulation results shown in figure 3 demonstrate the ability of the algorithm to effectively simulate the tumour response to a standard irradiation scheme for different OER values or fragmented) alike. All of the above-mentioned cells contribute to the tumour volume that is detectable by imaging techniques.
Both values of OER β appear to produce practically the same effect on the tumour response to the standard irradiation scheme. Therefore, the selection of either value of OER β (3.0 or 3.5) seems not to be a dominant factor. Simulation results agree with typical monolayer cell culture survival curves for OER β 3.0 and 3.5 as shown in figure 4(a) .
The simulation results suggest the superiority of the accelerated against the standard fractionation scheme for the specific tumour under consideration. This in silico observation can be made exclusively from the tumour control point of view and refers at least to the initial stages of the radiotherapeutic course. The tumour behaviour corresponding to the first simulated week appears to be practically the same for both the standard and the accelerated fractionation schemes (figure 5). After the first week, the total number of tumour cells in the case of accelerated fractionation is less compared to the case of standard fractionation. It should be noted that the irradiation effects on the surrounding normal tissues have not been taken into account. Modelling of these effects is currently under way. Both the treatment schemes evoke tumour depletion but accelerated fractionation is predictably more effective in the short term because it delivers 60 Gy in three weeks compared to six weeks for the standard fractionation. Nevertheless, after approximately 45 days from the beginning of the irradiation scheme, the surviving dormant tumour cells (in the case of the accelerated scheme) seem to 'wake' and proliferate (figure 5). Figure 6 provides a two-dimensional visualization of the simulated response of a clinical glioblastoma multiforme tumour to the standard fractionation scheme for a specific range of OER values (1.0, 2.5, 3.5). At the end of day 4, the tumour with OER = 1 appears to be more radiosensitive compared with tumours with OER = 2.5 and 3.5 as more of its cells appear to be killed at the same instant (figures 6(a), (e) and (i)). At the end of day 6, all tumours are strongly affected by radiation treatment whereas the highest number of proliferating cells is contained in the most hypoxic tumour ( figure 6( j) ). According to the adopted colouring criterion slices (b), (f ), ( j) have been painted with the necrotic area colour. At the beginning of the first day of the second week (day 8) newly produced proliferating cells are present in sufficient numbers to be apparent in (g) and (k). The population of the proliferating cells is larger in (k) compared to (g), while the whole slice of tumour (c) is still painted as 'necrotic'. The tumour represented by slice (k) seems to be more radioresistant than the tumours represented by slices (c) and (g). This can be attributed to the higher OER value of tumour (k). On the 12th day from the beginning of the radiotherapy course all tumours have started to shrink, but at different rates. The tumour represented by slice (d) (with OER = 1) is the most radiosensitive and is the fastest shrinking among the three tumours considered. Figure 7 depicts the corresponding simulation results if the cell cycle duration T c is considered to be 48 h and 60 h. During the entire standard fractionation course (42 days) both tumours show a similar response to irradiation. After completion of the radiotherapy course Figure 6 . Two-dimensional visualization of the simulated response of a clinical glioblastoma multiforme tumour to the standard fractionation scheme for a range of OER values. A centrally located horizontal slice of a tumour with OER = 1.0 (a) 4 fictitious days after the beginning of the radiotherapy course, (b) 6 fictitious days after the beginning of the radiotherapy course, (c) 8 fictitious days after the beginning of the radiotherapy course, (d) 12 fictitious days after the beginning of the radiotherapy course. A centrally located horizontal slice of a tumour with OER = 2.5 (e) 4 fictitious days after the beginning of the radiotherapy course, (f ) 6 fictitious days after the beginning of the radiotherapy course, (g) 8 fictitious days after the beginning of the radiotherapy course, (h) 12 fictitious days after the beginning of the radiotherapy course. A centrally located horizontal slice of the tumour with OER = 3.5 (i) 4 fictitious days after the beginning of the radiotherapy course, (j) 6 fictitious days after the beginning of the radiotherapy course, (k) 8 fictitious days after the beginning of the radiotherapy course, (l) 12 fictitious days after the beginning of the radiotherapy course. Colour code: dark grey: proliferating cell layer, light grey: dormant cell layer (G0), white: dead cell layer. The colouring criterion '99.8%' used to visualize the predictions has been defined as follows. 'For a geometrical cell of the discretizing mesh, if the percentage of dead cells is lower than 99.8% then {if percentage of proliferating cells > percentage of G0 cells, then paint the geometrical cell dark grey (proliferating cell layer), else paint the geometrical cell light grey (G0 cell layer)} else paint the geometrical cell white (dead cell layer)'. and before the 60th day the tumour with T c = 48 h appears to be more difficult to control than the one with T c = 60 h ( figure 7 (a) ). In the same period and for the tumour with T c = 48 h, a significant number of surviving dormant tumour cells 'wake up' and re-enter the cell cycle together with the surviving proliferating tumour cells. Figure 7 (c) demonstrates the ability of the model to adequately simulate both cell death and conformal tumour shrinkage. Figure 8 shows how two GBM tumours differing only in p53 status respond to the standard radiotherapy course. For the entire duration of radiotherapy and two weeks after its completion, the tumour with wt p53 exhibits a better response to irradiation. This is in agreement with the current literature data according to which p53 mutations in human malignancies are associated with poor prognosis, tumour relapse and poor response to therapy (Hass-Kogan et al 1996) .
Systematic comparison with clinical data is expected to lead to more clinically adapted parameter values. Further details on the simulation sequences and the visualization criteria can be found in the corresponding figure captions. 
Discussion
The CMA shrinkage algorithm introduced in this paper has produced a more realistic tumour shrinkage than the one achieved by Stamatakos et al (2002) . This is in accordance with Perez and Brady (1998, p 10) . Additionally, the imaging-based neovasculature distribution has been in agreement with Steel (2002, p 160-161) .
Furthermore, a parametric study of the influence of the cell cycle duration, OER, OER α and OER β in tumour growth, shrinkage and response to irradiation under different fractionation schemes has been made for three different cases of glioblastoma multiforme. According to the model predictions, and predictably, a whole tumour with shorter T c tends to repopulate faster. Furthermore, a higher OER value for the dormant cells leads to a more radioresistant whole tumour. A small variation of the OER β value (3.0 or 3.5) does not seem to play a major role in the tumour response. Accelerated fractionation has proved to be superior to the standard scheme for OER = 3.0. Finally, a tumour lacking functional wt p53 has been characterized by an inferior response to irradiation. An increased radioresistance has been manifested by a tumour with high OER and/or mt p53. This is in accordance with the corresponding decrease in the values of the α, β parameters.
The predictions of all indicative simulations performed agree at least qualitatively with the clinical experience. Additionally, the predictions agree with the current literature. Furthermore, the results of the parametric study agree with data presented by Duechting (1990) , Duechting et al (1995) , Kocher and Treuer (1995) , Kocher et al (2000) and Steel (2002, p 158-68) .
A process of quantitative clinical adaptation and validation of the evolving model is ongoing in collaboration with several clinical centres. The clinical validation procedure involves comparison of the model predictions with pertinent clinical data before, during and after the radiotherapy course. It should be stressed that no modifications to the standard clinical practice are necessary for the clinical validation. The simulation model is just 'following' the clinical practice and activates a self-optimization procedure. Hence no major ethical concerns are expected to arise during the clinical validation-adaptation procedure. Better estimation of parameters such as the alpha and beta values of the LQ model and of the cell loss factor are expected to be early outcomes of the validation process. Generic parameter estimation techniques, such as the neural networks technique, taboo searching etc can be used to this end. Simulation of the effect of other treatment modalities on the tumour such as chemotherapy as well as simulation of the reaction of the adjacent normal tissues is under development. The fact that the simulation model has a clear modular character is expected to substantially facilitate its clinical adjustment and application.
Conclusion
Good qualitative agreement with clinical observations strengthens the applicability of the model to real situations. Further long-term systematic testing and adaptation of the model is in progress. Subsequently, an integrated and patient-individualized decision support and spatiotemporal treatment planning system is expected to emerge after completion of the necessary clinical adaptation and validation processes. Such a system is also expected to substantially contribute to the advancement of cancer research leading to further clarification of the mechanisms responsible for tumour growth and response to various treatments. Significantly, it could serve as an educational platform for professionals and patients by means of virtual reality demonstrations of the likely natural development and treatment responsiveness of specific cancers so that all groups might positively contribute to the discussion about treatment procedure.
